Category : HUMAN PRESCRIPTION DRUG LABEL DEA Schedule : none Marketing Status : New Drug Application INGREDIENTS AND APPEARANCE LABELER - Hikma Pharmaceuticals USA Inc.(001230762) PRINCIPAL DISPLAY PANEL NDC 0143-9621-01 1 mL Vial Cyanocobalamin Injection, USP Rx only 1,000 mcg/mL For IM or SC use ONLY Protect from light Contains Benzyl Alcohol NDC 0143-9621-25 Rx only Cyanocobalamin Injection, USP 1,000 mcg/mL For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 25 x 1 mL Vials PRINCIPAL DISPLAY PANEL NDC 0143-9620-01 10 mL Multiple Dose Vial Cyanocobalamin Injection, USP Rx only 10,000 mcg per 10 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative NDC 0143-9620-10 Rx only Cyanocobalamin Injection, USP 10,000 mcg per 10 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 10 x 10 mL Multiple Dose Vials PRINCIPAL DISPLAY PANEL NDC 0143-9619-01 30 mL Multiple Dose Vial Cyanocobalamin Injection, USP Rx only 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative NDC 0143-9619-10 Rx only Cyanocobalamin Injection, USP 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 10 x 30 mL Multiple Dose Vials NDC 0143-9619-01 Rx only Cyanocobalamin Injection, USP 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 1 x 30 mL Multiple Dose Vials PRINCIPAL DISPLAY PANEL
NNMT is an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH)
C., Austin, L
Furthermore, cholinergic signaling is commonly associated with satiating hunger and glutamatergic signaling is commonly associated with learning and memory
In turn, you stay motivated and consistent with exercise
We indicated our belief that this approach would help achieve our goal of ensuring pricing information is standardized and easily comparable across hospitals when a hospital's payer-specific negotiated charge is based on a percentage or algorithm, as well as the purpose of Executive Order 14221 to promote disclosure of a real price
